The effect of different methods of protecting the myocardium on lysosomal activation and acid phosphatase activity in the dog heart after one hour of cardiopulmonary bypass.
The present study was undertaken to determine the involvement of cardiac lyososomes in injury to the myocardium after cardiopulmonary bypass. Twenty conditioned mongrel dogs, weighing 15 to 18 kilograms, were fasted overnight, anesthetized with sodium pentobarbital (30 mg. per kilogram), intubated, and maintained on positive-pressure ventilation. The femoral artery and femoral vein were cannulated for pressure measurements. After median sternotomy, intravenous heparin was administered (3 mg. per kilogram) before the aorta and the superior and inferior venae cavae were cannulated for bypass. Bypass was instituted with a Travenol modular pump and a Bentley pediatric bubble oxygenator and heat exchanger. The ultrastructural effects on the myocardium and the acid phosphatase activity in the left ventricle were compared in dogs exposed to bypass for 1 hour with varying types of myocardial support: perfusion of the coronary arteries, normothermic ischemic arrest, or selective cardiac hypothermia. The morphology of control hearts and hearts fixed after 1 hour of coronary perfusion were similar. The distribution and structure of subcellular lysosomes were the same and showed identical patterns of acid phosphatase activity. Normothermic ischemic arrest was associated with a loss of glycogen stores, disrupted sarcoplasmic reticulum and T tubules, vacuolization and decrease in matrix density of mitochondria, and separation of the intercalated discs. Lysosomal activity was absent except for occasional residual bodies in the nuclear pole zone of the myocardial cells. Selective cardiac hypothermia produced results superior to those from normothermic ischemic arrest. Although these hearts showed proliferation of the lysosomal compartment, the organelles responsible for excitation-contraction coupling were spared.
D000135:Acid Phosphatase / Q000378:metabolism*; D000818:Animals; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D004285:Dogs; D005112:Extracorporeal Circulation / Q000009:adverse effects*; D006003:Glycogen / Q000378:metabolism; D006323:Heart Arrest / Q000209:etiology / Q000517:prevention & control; D006331:Heart Diseases / Q000209:etiology / Q000517:prevention & control*; D008247:Lysosomes / Q000201:enzymology*; D008931:Mitochondria, Muscle / Q000648:ultrastructure; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure*; D012519:Sarcoplasmic Reticulum / Q000648:ultrastructure; D013997:Time Factors
D006003:Glycogen; D000135:Acid Phosphatase